References
- Kuypers DRJ, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341–58.
- Knight SR, Morris PJ. Does evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675–85.
- Bruchet NK, Emson MHH. Limited sampling strategies for mycophenolic acid in solid transplantation: a systematic review. Expert Opin Drug Metab Toxicol. 2009;5:1079–97.
- Kamphues C, Bova R, Röcken C, Neuhaus R, Pratschke J, Neuhaus P, Safety of mycophenolate monotherapy in patients after liver transplantation. Ann Transplant. 2009;14:40–6.
- DRUGDEX® Evaluations. Mycophenolic acid. Available at: www.micromedex.com/products/drugdex (Accessed June 9, 2010).
- van Gelder T, Saw LM. The rationale for and limitations of therapeutic drug monitoring of mycophenolate mofetil in transplantation. Transplantation. 2005;80:S244–53.
- Shin M, Moon JI, Kim JM, Choi GS, Kwon CH, Kim SJ, Pharmacokinetics of mycophenolic acid in living donor liver transplantation. Transpl Proc. 2010:42:846–53.
- Hale MD, Nicholls AJ, Bullingham RES, Hené R, Hoitsma A, Squifflet JP, The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672–83.
- Nashan B, Saliba F, Durand F, Barcena R, Herrero JI, Mentha G, Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl. 2009;15:136–47.
- Van Gelder T, Le Meur Y, Shaw LM, Oellerich M, De Nofrio D, Holt C, Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145–54.
- Holt DW. Monitoring mycophenolic acid. Ann Clin Biochem. 2002;39:173–83.
- Okamura A, Yamamori M, Shimoyama M, Kawano Y, Kawano H, Kawamori Y, Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogenic hematopoietic stem cell transplantation. Int J Hematol. 2008;88:104–10.
- Jacobson P, El-Massah SF, Rogosheske J, Kerr A, Long-Boyle J, DeFor T, Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transpl. 2009;44:113–20.
- Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Unrelated domor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transpl. 2006;12:454–65.
- David-Neto E, Pereira LM, Kakehashi E, Sumita NM, Mendes ME, Castro MCR, The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transpl. 2005;19:19–25.
- Hao C, Anwei M, Bing C, Baiyong S, Weixia Z, Chuan S, Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transpl. 2008;14:1165–73.
- Brunet M, Cirera I, Martorell J, Vidal E, Millán O, Jiménez O, Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation. 2006;81:541–6.